The Inflation Reduction Act (IRA) was signed into law on August 16, 2022. This groundbreaking law requires that HHS Secretary negotiate pricing for certain Medicare covered drugs and manufacturers pay annual rebates to Medicare for price increases above a set threshold. It additionally eliminates enrollee cost sharing for certain vaccines, sets a $35 limit on enrollee cost sharing for insulin, expands premium tax credit eligibility and amount, and eliminates the eligibility phaseout for households with annual incomes above 400% of the federal poverty level, among other provisions. This session will explore the multi-faceted implications of the IRA on industry and the state of public health, as well as benefits and risks posed by implementing this framework, including impacts on prescription drug affordability, generic drugs, orphan drug exclusivity, differential treatment between small molecules and biologics, and strategy shifting for industry.

Get Access

  • +$100 for nonmembers

Internet Explorer and Microsoft Edge are not supported by the checkout process.

Please use Chrome, Firefox, or Safari.  If you are unable to use these browsers, please contact us at 202-371-1420 or [email protected] and we will assist you.


Lynn W. Mehler, Partner, Hogan Lovells US LLP
John A. Murphy, Chief Policy Officer Deputy Counsel, Healthcare, Biotechnology Innovation Organization (BIO)
Nancy E. Taylor, Shareholder, Greenberg Traurig, LLP
Eva Temkin, Partner, King & Spalding LLP

Virtual Learning FAQ

On-demand webinar content is sent via email as soon as we are able to process and verify your order. This usually occurs within 1 business day.


On-demand content can be played back on most devices.


CLE credit is not currently available for pre-recorded sessions.

Related Content